Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

UPSA claims new COX-2 inhibitors for inflammation, pain and other disorders

Dec. 31, 1997

FDA approves Arthrotec, a new arthritis medication with NSAID efficacy and improved GI safety

Dec. 30, 1997

New antiinflammatory compounds disclosed by Glycomed

Dec. 30, 1997

Alexion files IND for C5 inhibitor treatment for rheumatoid arthritis

Dec. 29, 1997

Phase IIb trial of TCR vaccine for rheumatoid arthritis begins

Dec. 29, 1997

Procter & Gamble's COX-2 inhibitor in preclinical testing

Dec. 24, 1997

Hyal discontinues development of osteoarthritis drug

Dec. 18, 1997

Pennsaid submitted to FDA for approval

Dec. 16, 1997

Selective COX-2 inhibitors under development at Merck Frosst

Dec. 16, 1997

Diphosphonate antiarthritic agent developed at Toray

Dec. 12, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...